Oxford BioTherapeutics

Contact
OxfordBioTherapeutics.com
+441235861770

Oxford BioTherapeutics Ltd

94a Milton Park
OX14 4RY Abingdon
United Kingdom

Phone

OxfordBioTherapeutics.com
Contact
Profile Products News
Contact

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines for oncology. OBT’s strategy is to develop innovative antibody-based cancer drugs, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP® proteomic database. Through its alliances with the world leaders in antibody development (Medarex, Biosite and Amgen), OBT is in an unrivalled position to convert its novel targets into a successful therapeutic pipeline. OBT’s pipeline will deliver innovative and cost-effective medicines to fulfil major unmet patient needs in the field of cancer. OBT, a privately held company, was formed in 2004 and is based near Oxford, UK.

Read more about Oxford BioTherapeutics
Facts about Oxford BioTherapeutics
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Oxford BioTherapeutics

Product portfolio

Show all

News about Oxford BioTherapeutics

Oxford BioTherapeutics

27-Nov-2014 | business & finance

$1 Billion Oncology Alliance Initiates First-in-Human Study of Enhanced Antibody for Treatment of Acute Myeloid Leukemia

Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announced that they have initiated the first-in ...

Read news
Oxford BioTherapeutics

31-Oct-2012 | business & finance

Menarini Group and Oxford BioTherapeutics sign Major Strategic Collaboration for the Clinical Development and Manufacture of a Portfolio of Novel Antibody-Based Cancer Drugs

Menarini and Oxford BioTherapeutics (OBT) announced a major strategic alliance  to develop a portfolio of antibody-based drugs in the field of cancer. The ...

Read news
Oxford BioTherapeutics

04-May-2012 | people

Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel

Oxford BioTherapeutics (OBT) announced the appointment of Dr Esteban Pombo-Villar as Chief Operations Officer (COO) of the OBT group. In this position he ...

Read news
Oxford BioTherapeutics

15-Sep-2011 | research and development

Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer

Companies to combine proprietary technologies to generate novel ADC product candidates

Read news
Oxford BioTherapeutics

27-Jan-2011 | business & finance

Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers

Oxford BioTherapeutics (OBT) announced that sanofi-aventis has acquired an exclusive world-wide license to one of OBT’s internal preclinical antibody ...

Read news
Oxford BioTherapeutics

10-Dec-2009 | people

Oxford BioTherapeutics Appoints Michael Moore as Chairman

Oxford BioTherapeutics (OBT) has announced the appointment of Dr Michael Moore as non-executive Chairman. Dr Moore has several decades of senior ...

Read news
Oxford BioTherapeutics

20-May-2009 | business & finance

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

Oxford BioTherapeutics (OBT) announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for ...

Read news
Oxford BioTherapeutics

03-Dec-2008 | business & finance

Oxford Genome Sciences Changes its Name to Oxford BioTherapeutics

Oxford Genome Sciences announced that it has changed its name to Oxford BioTherapeutics (OBT). The new name will take effect immediately. According to the ...

Read news
Show more news about Oxford BioTherapeutics

Here you will find Oxford BioTherapeutics Ltd